Gold vs. crypto: Which should investors own in debasement trade?
00:00 Speaker A
Lisa, on this debasement trade, uh, one, are you more inclined A to play it long still, uh, or do you think it’s a little bit long in the tooth? And if you are still bullish on this or bullish, uh, on it at all,
» Read more about: Gold vs. crypto: Which should investors own in debasement trade? »
Read MoreBitcoin ETFs Continue To Attract Capital, With DefiMiner Leading The New Trend In Cloud Mining.
The second-highest net capital inflow by mainstream investors since launch was observed in Bitcoin spot ETFs in October 2025. The consistent inflow of funds is enhancing market perception and elevating Bitcoin’s liquidity and impact.
DefiMiner has become a preferred choice for digital asset investors, in line with the growing industry. Offering users high returns,
Read MoreStock market today: Dow, S&P 500, Nasdaq steady after latest record-setting rally
Top 3 Cryptocurrency Buys for October 2025 Bull Run: Ozak AI's $0.012 Entry Compared to BTC, ETH, SOL October Opportunities
Ozak AI has sold over 930 million in its presale, raising a remarkable $3.56 million, with an entry price of $0.012. The success indicates the confidence of investors in the future of the project, and the next stage of the presale will raise the price of the tokens to $0.014. The emphasis of the platform on decentralized financial intelligence and its innovative predictive models has drawn a lot of attention,
Read MoreChina says will 'fight to the end' in US trade war
BEIJING: China said on Tuesday (Oct 14) it was ready to “fight to the end” in a trade war with the United States after President Donald Trump said he would impose an additional 100 per cent tariff on the world’s second-largest economy.
“On the matter of tariff wars and trade wars,
» Read more about: China says will 'fight to the end' in US trade war »
Read MoreThe Burst
Market Commentary: The Meteoric Rise of Eli Lilly
Did you know that Eli Lilly and other pharmaceutical companies have sold approximately 10.6 million shots of obesity drug doses in the U.S. in a single month? The rise of these injectable weight loss medications is so powerful that it’s causing investors to question the future of even staple food and beverage stocks.
While this aspect alone could secure Eli Lilly as the pharmaceutical golden goose you’ve been looking for there is much more than meets the eye.
» Read more about: Market Commentary: The Meteoric Rise of Eli Lilly »
Read MoreThe Ivy
1 Billion Reasons to Buy This Under-the-Radar Stock
Urban air mobility was once the stuff of sci-fi movies but in 2009 Joby was built to bring the future to the present. It has built an EV takeoff and landing aircraft that has won votes of confidence from the likes of manufacturing giant Toyota.
The big idea behind the firm is to reduce traffic congestion by making sustainable air transportation affordable and safe.
» Read more about: 1 Billion Reasons to Buy This Under-the-Radar Stock »
Read More